- Home
- RMI vs TLPH Comparison
RMI vs TLPH Comparison
Compare RMI & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
BUY
Current Price
$1.07
Company Overview
Basic Information| Metric | RMI | TLPH |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.8M | 70.3M |
| IPO Year | 2018 | 2010 |
Fundamental Metrics
Financial Performance| Metric | RMI | TLPH |
|---|---|---|
| Price | $13.60 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.13 |
| AVG Volume (30 Days) | 22.5K | ★ 148.3K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.11 | $0.69 |
| 52 Week High | $16.36 | $1.57 |
Technical Indicators
Market Signals| Indicator | RMI | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 36.17 | 38.28 |
| Support Level | $13.11 | $0.76 |
| Resistance Level | $15.61 | $1.13 |
| Average True Range (ATR) | 0.47 | 0.04 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 28.49 | 33.33 |
Price Performance
Historical Comparison RMI
TLPH
About RMI RiverNorth Opportunistic Municipal Income Fund Inc.
RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.